AstriVax

Ambachtenlaan 1
Heverlee 3001
BE
AstriVax
Foundation date
30/06/2022
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.
Upcoming events
All events-
1212 '23
BioFIT 2023
Event by: Eurasanté -
0602 '24
Discovery to Innovation in Animal Health - 2024
Event by: Ghent University, Provaxs, Paul Dick & Associates -
3011 '23
The GxP Academy: Aseptische Training en werken in LAF/Biosafety Cabinet
Event by: Advipro
Latest news
More news-
argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia
19 hours ago
Read more
-
Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
Wednesday November 22nd 2023
Read more
-
argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis
Thursday November 16th 2023
Read more
Jobs by AstriVax
More jobsMore info?
Ellen Telleir
Communication Coordinator